Biogen Inc. (BIIB) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Biogen Inc. stock price, BIIB
Biogen Inc. stock chart:
Biogen Inc. close price: 254.84
Stock price forecast:
UP TO +8.42%
Total forecasts: 82
Reached: 67 (81.71%)
Total Win: 395.64 (143.04%)
Showing 1-10 of 478 items.
|Date of Forecast||Stock Price||Target Price||Forecast Reached Date|
Biogen Inc. latest news:
What's Worrying Me About Biogen
Biogen could struggle to maintain its market-leading position in multiple sclerosis over the next two years.
Biogen stock rises after first-quarter earnings, profit beat
Biogen Inc. shares rose as much as 4.8% in premarket trade Tuesday after the company reported a first-quarter earnings and profit beat. Earnings for the latest quarter declined to $747.6 million, or $3.46 per share, from $970.9 million, or $4.43 per share, in the year-earlier period. The latest results include the $263 million cost of a settlement and license agreement with Forward Pharma , Biogen said. Adjusted earnings-per-share were $5.20, compared with the FactSet consensus of $4.97. Revenue rose to $2.81 billion from $2.73 billion, compared with the FactSet consensus of $2.73 billion. Revenue from Biogen's key multiple sclerosis drug, Tecfidera, rose to $958.2 million from $945.2 million, below the FactSet consensus of $977.5 million. Biogen shares have surged 10.0% over the last three months, compared with a 3.3% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Biogen wins Tecfidera U.S. patent dispute with Forward Pharma
A U.S. patent board on Friday ruled against Danish drugmaker Forward Pharma A/S (FWP), finding Biogen's patents on its blockbuster multiple sclerosis drug Tecfidera to be valid. The ruling by the U.S. Patent Trial and Appeal Board frees Bigoen Inc from future royalty payments to Forward and sent the Danish firm's shares down nearly 20 percent.
Biogen stock rises, Forward Pharma halted down 20% after patent ruling
Shares of Biogen Inc. rose Friday, while Forward Pharma A/S shares were halted after falling almost 20%, after Biogen was reported to have won a patent ruling. The U.S. Patent Office ruled in favor of Biogen in a patent interference proceeding related to its multiple sclerosis drug Tecfidera, according to Evercore ISI analyst Umer Raffat. Biogen paid Forward Pharma $1.25 billion in February related to the patent that covers ways of treating MS patients. Raffat said Biogen would have been on the hook for royalty payments of about $300 million annually starting in 2021, if it had lost the patent ruling. Biogen shares were up 1.2% Friday, but have gained just 4% year-to-date, while the S&P 500 has gained almost 6%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Biogen wins ruling in Tecfidera IP case; shares rise
Biogen Inc(BIIB) on Tuesday won an intellectual property rights ruling against hedge fund manager Kyle Bass over its top multiple sclerosis pill, Tecfidera, pushing shares up more than 1 percent on a day when most U.S. stocks were down. The ruling came from the U.S. Patent and Trademark Office's Patent Trial and Appeal Board in Washington.
BioLife Solutions, Inc.BLFS
BioMarin Pharmaceutical Inc.BMRN
BiondVax Pharmaceuticals Ltd.BVXV
BiondVax Pharmaceuticals Ltd.BVXVW
Bio-Path Holdings, Inc.BPTH
BioShares Biotechnology Clinical Trials FundBBC
BioShares Biotechnology Products FundBBP